G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain

Target: LRRK2 Composite Score: 0.790 Price: $0.79 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
B+
Composite: 0.790
Top 9% of 1222 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
A Mech. Plausibility 15% 0.86 Top 15%
A Evidence Strength 15% 0.83 Top 10%
C Novelty 12% 0.48 Top 97%
A+ Feasibility 12% 0.91 Top 16%
A Impact 12% 0.88 Top 17%
A+ Druggability 10% 0.93 Top 15%
B Safety Profile 8% 0.67 Top 30%
B+ Competition 6% 0.72 Top 38%
A Data Availability 5% 0.82 Top 18%
A Reproducibility 5% 0.80 Top 18%
Evidence
2 supporting | 2 opposing
Citation quality: 0%
Debates
1 session B+
Avg quality: 0.74
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity?

The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation, but it's unclear whether this represents true signal amplification during lysosomal swelling or just a higher activity floor. This distinction is crucial for understanding disease mechanisms and therapeutic targeting. Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (4)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Mutant-dependent amplification is context-dependent and strongest in microglia and macrophages
Score: 0.740 | Target: LRRK2,RAB10
A downstream LRRK2-Rab10-JIP4 lysosomal stress loop promotes alpha-synuclein release and propagation
Score: 0.680 | Target: LRRK2,RAB10,JIP4,SNCA
Rab12 may better report chronic lysosomal stress biology than Rab10 in G2019S contexts
Score: 0.670 | Target: RAB12
LYTL and JIP4-dependent lysosomal remodeling may show mutant-selective amplification even when bulk phospho-Rab changes are modest
Score: 0.580 | Target: JIP4,LRRK2,RAB10,RAB35

→ View full analysis & all 5 hypotheses

Description

The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact. In this view, mutant cells begin from a higher activity floor, and the key experimental discriminator is whether baseline-normalized EC50, slope, or Emax materially increase during graded swelling.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.86 (15%) Evidence 0.83 (15%) Novelty 0.48 (12%) Feasibility 0.91 (12%) Impact 0.88 (12%) Druggability 0.93 (10%) Safety 0.67 (8%) Competition 0.72 (6%) Data Avail. 0.82 (5%) Reproducible 0.80 (5%) 0.790 composite
4 citations 4 with PMID Validation: 0% 2 supporting / 2 opposing
For (2)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
1
MECH 3CLIN 1GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Endogenous G2019S shows only modest phospho-Rab el…SupportingMECH----PMID:34125248-
Membrane recruitment is sufficient to trigger Rab …SupportingMECH----PMID:35580815-
Existing studies do not cleanly separate baseline …OpposingMECH----PMID:35580815-
Elevated phospho-Rab biomarkers in carriers could …OpposingCLIN----PMID:39705401-
Legacy Card View — expandable citation cards

Supporting Evidence 2

Endogenous G2019S shows only modest phospho-Rab elevation compared with stronger ROC-COR mutants, consistent w…
Endogenous G2019S shows only modest phospho-Rab elevation compared with stronger ROC-COR mutants, consistent with a modest catalytic bias rather than a major gain increase.
Membrane recruitment is sufficient to trigger Rab phosphorylation, implying recruitment may be the main activa…
Membrane recruitment is sufficient to trigger Rab phosphorylation, implying recruitment may be the main activation event and G2019S may add a higher baseline set-point onto that pathway.

Opposing Evidence 2

Existing studies do not cleanly separate baseline offset from stimulus gain under endogenous graded lysosomal …
Existing studies do not cleanly separate baseline offset from stimulus gain under endogenous graded lysosomal swelling conditions.
Elevated phospho-Rab biomarkers in carriers could also reflect altered membrane dwell time, substrate access, …
Elevated phospho-Rab biomarkers in carriers could also reflect altered membrane dwell time, substrate access, or phosphatase balance rather than a simple baseline-only effect.
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-24 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

  • Title: `G2019S raises the LRRK2 kinase floor more than the swelling gain`

  • Mechanism: G2019S may primarily increase constitutive catalytic output, producing higher baseline pRab10/pRab12 without materially changing the slope of the lysosomal volume-response curve. In this model, swelling still activates the same upstream lysosomal recruitment/activation circuit, but mutant cells start from a higher baseline rather than showing stronger fold-amplification.

    Target gene/protein/pathway: `LRRK2` kinase domain, `RAB10`, `RAB12`, lysosomal stress signaling

    **Supporting e

    🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

    Skeptical Read

    The main weakness across all six is the same: most cited evidence shows that mutant `LRRK2` can elevate phospho-Rab output or alter lysosomal remodeling, but it does not cleanly separate `baseline offset` from `stimulus gain`. Much of the literature uses overexpression, artificial membrane targeting, `LLOME` or lysosomotropic stress, PBMCs, or macrophage-like cells. Those systems are useful for mechanism discovery, but they are not decisive for the specific question “does G2019S amplify volume sensing, or just raise the floor?”

  • **`G2019S raises the kinase floor more
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    As of April 24, 2026, the hypotheses that most credibly survive are:

  • #1 Higher baseline kinase activity more than higher swelling gain
  • #4 Amplification is context-dependent and strongest in microglia/macrophages
  • #5 `pRab12` may be the better translational biomarker under chronic lysosomal stress
  • #6 A downstream `LRRK2-Rab10/JIP4` lysosomal stress to α-syn release loop is plausible
  • #2 LYTL/JIP4 remodeling is a useful mechanistic phenotype, but not yet a primary therapeutic thesis
  • #3 phosphatase buffering survives as an assay-interpretation modifier,

    Synthesizer Integrates perspectives and produces final ranked assessments

    {
    "ranked_hypotheses": [
    {
    "title": "G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain",
    "description": "The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact. In this view, mutant cells begin from a higher activity floor, and the key experimental discriminator is whether baseline-normalized EC50, slope, or Emax materially increase during graded swelling."

    Price History

    No price history recorded yet

    7d Trend
    Stable
    7d Momentum
    ▲ 0.0%
    Volatility
    Low
    0.0000
    Events (7d)
    0

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (3)

    Paper:34125248
    No extracted figures yet
    Directing LRRK2 to membranes of the endolysosomal pathway triggers RAB phosphorylation and JIP4 recruitment.
    Neurobiology of disease (2022) · PMID:35580815
    No extracted figures yet
    Paper:39705401
    No extracted figures yet

    📓 Linked Notebooks (0)

    No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    Related Hypotheses

    TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
    Score: 0.990 | neurodegeneration
    TREM2-Dependent Microglial Senescence Transition
    Score: 0.950 | neurodegeneration
    PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
    Score: 0.941 | neurodegeneration
    Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
    Score: 0.933 | neurodegeneration
    CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
    Score: 0.921 | neurodegeneration

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions

    No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

    Knowledge Subgraph (0 edges)

    No knowledge graph edges recorded

    3D Protein Structure

    🧬 LRRK2 — PDB 6VP6 Click to expand 3D viewer

    Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

    Source Analysis

    Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity?

    neurodegeneration | 2026-04-24 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)